Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin real-world study of serum uric acid in type 2 diabetes
ChiCTR2500103723Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Blood uric acid at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500103723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103723.